Phospho-GAB2 (Ser159) Antibody

What is GAB2 and what is the significance of its phosphorylation at Ser159?

GAB2 (GRB2-associated-binding protein 2) is a scaffolding adapter protein that plays crucial roles in transmitting signals downstream of various receptors including cytokine, growth factor, and antigen receptors. Phosphorylation at Ser159 is particularly significant as it represents a key regulatory site that modulates GAB2's function in signal transduction pathways.

The serine 159 site corresponds to the RKSS160 motif in rat GAB2 and matches the PKA consensus phosphorylation motif RR/KXSP/TP. This phosphorylation serves as a critical regulatory mechanism that can inhibit GAB2 tyrosine phosphorylation and subsequent downstream signal amplification . Studies have shown that this phosphorylation precedes AKT(Ser473) phosphorylation, indicating its role in the sequential activation of downstream signaling pathways .

Which kinases are responsible for phosphorylating GAB2 at Ser159?

Based on the research literature, two main kinases have been identified as responsible for phosphorylating GAB2 at Ser159:

• PKA (Protein Kinase A): GAB2 is a direct PKA target. Ser159 on GAB2 matches the PKA consensus phosphorylation motif RR/KXSP/TP. Evidence shows that GAB2 is selectively immunoprecipitated using anti-p-PKA substrate antibodies that recognize RXXSP/TP motifs and can be phosphorylated in immune complex phosphorylation reactions in the presence of the catalytic subunit of PKA .

• AKT/PKB (Protein Kinase B): In certain contexts, particularly in breast cancer cell lines like MCF-7, AKT has been shown to phosphorylate GAB2 on Ser159. This has been demonstrated through in vitro kinase assays where GAB2 was effectively phosphorylated by constitutively active forms of PKB, and this phosphorylation was completely abolished when S159A GAB2 (mutant where Ser159 is replaced with alanine) was used as the substrate .

The kinase responsible may vary depending on cellular context and stimulus type.

What are the primary research applications for Phospho-GAB2 (Ser159) antibodies?

Phospho-GAB2 (Ser159) antibodies are valuable tools for studying signaling pathways and have several key applications:

• Signaling pathway analysis: Detecting activation state of GAB2-mediated signaling in response to various stimuli, particularly in FSH, growth factor, and immune receptor signaling .

• Protein-protein interaction studies: Investigating how Ser159 phosphorylation affects GAB2's interactions with binding partners such as IRS-1, PI3K subunits, and receptor tyrosine kinases .

• Cancer research: Studying the role of GAB2 phosphorylation in cancer cell signaling, particularly in breast cancer and leukemia models .

• Pharmaceutical research: Evaluating effects of kinase inhibitors and other drugs on GAB2-dependent signaling pathways .

• Temporal signaling studies: Tracking the timing of GAB2 phosphorylation in relation to other signaling events, as phosphorylation of GAB2(Ser159) has been shown to precede phosphorylation of AKT(Ser473) .

What methods can be used to study GAB2 phosphorylation at Ser159?

Several complementary methods are typically employed to study GAB2 phosphorylation at Ser159:

Research shows that anti-p-GAB2(Ser159) antibody readily pulls down IRS-1 but surprisingly does not pull down RI, indicating selective association of phosphorylated GAB2 with certain binding partners . This highlights the importance of using multiple complementary techniques to fully characterize phosphorylation-dependent interactions.

What are appropriate positive and negative controls when using Phospho-GAB2 (Ser159) antibodies?

Proper controls are essential for experiments using Phospho-GAB2 (Ser159) antibodies:

Positive controls:

• HT29 cells treated with serum (20%, 15 minutes) have been validated as a positive control for Western blot applications .

• FSH-treated granulosa cells (GCs) show robust phosphorylation of GAB2 at Ser159 .

• Cell lysates from cells expressing constitutively active PKA or AKT/PKB .

Negative controls:

• Untreated/serum-starved cells that express GAB2 but have minimal Ser159 phosphorylation.

• Lysates from cells treated with PKA inhibitors (e.g., H89) or PI3K/AKT pathway inhibitors (e.g., wortmannin) .

• Peptide competition assays where the phospho-specific antibody is pre-incubated with the phosphorylated peptide immunogen (several commercial antibodies include blocking peptides for this purpose) .

• Ideally, cells expressing the S159A GAB2 mutant where the serine is replaced with alanine, preventing phosphorylation at this site .

For phospho-specific western blots, it's recommended to strip and reprobe membranes with antibodies against total GAB2 to normalize phospho-signals to total protein expression levels.

How can researchers optimize immunoblotting protocols for detecting phosphorylated GAB2?

Optimizing immunoblotting for phosphorylated proteins requires special considerations:

• Sample preparation:

  • Rapid cell lysis in buffers containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, beta-glycerophosphate) is critical.

  • Maintain cold conditions throughout lysis and processing to minimize dephosphorylation.

  • For studies involving PKA-mediated phosphorylation, consider including PKA inhibitors in lysis buffers.

• Gel electrophoresis and transfer:

  • Use fresh polyacrylamide gels (10-12%) for optimal resolution of GAB2 (~98 kDa).

  • For detecting phosphorylated GAB2, wet transfer methods often yield better results than semi-dry transfers.

• Blocking and antibody incubation:

  • BSA-based blocking solutions (3-5% BSA in TBST) are generally preferred over milk for phospho-specific antibodies.

  • Typical dilutions for commercial Phospho-GAB2 (Ser159) antibodies range from 1:500 to 1:2000 for Western blotting .

  • Overnight incubation at 4°C often improves signal-to-noise ratio.

• Detection and quantification:

  • Enhanced chemiluminescence (ECL) systems provide sufficient sensitivity for most applications.

  • Quantify band intensities using appropriate software and normalize phospho-GAB2 signals to total GAB2.

• Verification approach:

  • Consider using multiple antibodies from different sources when possible.

  • Validate findings with functional studies using GAB2 phosphorylation site mutants (S159A) .

How does phosphorylation at Ser159 affect GAB2's role in signal transduction?

The phosphorylation of GAB2 at Ser159 has profound effects on its function in signal transduction:

• Inhibition of tyrosine phosphorylation: Ser159 phosphorylation negatively regulates GAB2 tyrosine phosphorylation downstream of various receptors. Research shows that expression of constitutively active PKB reduces GAB2 tyrosine phosphorylation by 40-90%, depending on the variant used .

• Alteration of protein-protein interactions: Phosphorylation at Ser159 changes GAB2's interaction with binding partners. Studies demonstrate that phosphorylated GAB2(Ser159) readily associates with IRS-1 and PI3K (p85), but surprisingly, does not maintain its interaction with the regulatory subunit of PKA (RI) .

• Modified receptor coupling: Expression of GAB2 mutated at Ser159 (S159A) enhances association with receptors like ErbB2, leading to increased tyrosine phosphorylation of the receptor and amplification of downstream signaling pathways including ERK and PKB .

• Temporal regulation of signaling: Phosphorylation of GAB2(Ser159) precedes the phosphorylation of AKT(Ser473), suggesting it plays a role in the sequential activation of downstream signaling events .

• Feedback inhibition: This phosphorylation represents a negative feedback mechanism, as AKT can phosphorylate GAB2 at Ser159, which in turn inhibits further signal amplification through GAB2 .

The significance of this phosphorylation is highlighted by studies showing that a GAB2 mutant unable to be phosphorylated at Ser159 (S159A) exhibits enhanced transforming activity in fibroblasts, suggesting that this regulatory mechanism helps prevent aberrant cellular signaling .

What is the relationship between GAB2 phosphorylation at Ser159 and tyrosine phosphorylation sites?

Research has revealed complex interplay between Ser159 phosphorylation and tyrosine phosphorylation sites on GAB2:

• Inverse relationship: Phosphorylation at Ser159 generally inhibits tyrosine phosphorylation of GAB2. When S159A GAB2 (mutant that cannot be phosphorylated at this site) is expressed, enhanced tyrosine phosphorylation is observed in response to stimuli like HRG (heregulin) .

• Specific tyrosine sites affected: While the search results don't specify all affected tyrosine sites, research indicates that Tyr452 is a significant tyrosine phosphorylation site on GAB2 . The relationship between Ser159 phosphorylation and phosphorylation at Tyr452 appears important for signaling regulation.

• Influence on adapter function: Tyrosine-phosphorylated GAB2 serves as a docking platform for SH2 domain-containing proteins like SHP2 and the p85 subunit of PI3K. Ser159 phosphorylation modulates these interactions by regulating the availability of phosphorylated tyrosine residues.

• Temporal regulation: Evidence suggests a sequential process where Ser159 phosphorylation can follow or precede tyrosine phosphorylation depending on the stimulus and cellular context. In certain systems, phosphorylation of GAB2(Ser159) precedes phosphorylation of AKT(Ser473) .

• Dual phosphorylation: In certain contexts, such as neutrophil activation, GAB2 can undergo dual phosphorylation at both Ser/Thr and Tyr residues through different receptor mechanisms, suggesting complex integration of multiple signaling inputs .

This relationship is particularly important in understanding how GAB2 integrates signals from multiple upstream activators and regulates downstream pathway activation.

What role does GAB2 Ser159 phosphorylation play in leukemia development and progression?

Recent evidence indicates that GAB2 and its phosphorylation status play important roles in leukemia, particularly in Acute Myeloid Leukemia (AML):

• FLT3-ITD driven leukemia: GAB2 has been identified as a critical effector downstream of FLT3-ITD, a common mutation in AML. Research using a Flt3-ITD knock-in, Dnmt3a haploinsufficient mouse model demonstrated that Gab2 is essential for the development of Flt3-ITD driven AML in vivo .

• Survival and disease progression: Gab2 deficient mice displayed prolonged survival, attenuated liver and spleen pathology, and reduced blast counts in leukemia models. Furthermore, leukemic bone marrow from Gab2 deficient mice exhibited reduced colony-forming capacity and increased sensitivity to FLT3 inhibitors .

• Signaling pathway integration: Transcriptomic analysis identified genes encoding for Axl and the Ret co-receptor Gfra2 as targets of the Flt3-ITD/Gab2/Stat5 axis, suggesting that Gab2 promotes AML aggressiveness and drug resistance by incorporating additional receptor tyrosine kinases into the Flt3-ITD signaling network .

• Phosphorylation importance: While the search results don't specifically address Ser159 phosphorylation in leukemia, the regulatory role of this site in controlling GAB2's signaling capabilities suggests it may be important in modulating GAB2's contribution to leukemogenesis. The ability of Ser159 phosphorylation to inhibit tyrosine phosphorylation could potentially modulate interaction with PI3K and other effectors critical for leukemic cell survival and proliferation.

These findings identify GAB2 as a promising biomarker and therapeutic target in human AML, with potential implications for developing treatments that might modulate GAB2 phosphorylation status.

How can researchers distinguish between PKA-mediated and AKT-mediated phosphorylation of GAB2 at Ser159?

Distinguishing between PKA and AKT as the kinase responsible for GAB2 Ser159 phosphorylation requires careful experimental design:

• Kinase-specific inhibitors:

  • Use PKA-specific inhibitors (e.g., H89, PKI peptide, RIAD peptide) versus AKT-specific inhibitors (e.g., MK-2206, AKTi-1/2)

  • The selective RI anchoring disruptor (RIAD) has been shown to reduce AKT(Ser473) phosphorylation by 63.2 ± 11.6%, while a scrambled RIAD peptide (RSCR) reduced it by 32.5 ± 7.5%

• Pathway-specific stimulation:

  • Activate PKA using cAMP-elevating agents (forskolin, IBMX) or AKT using growth factors in the presence of PI3K inhibitors

  • FSH has been shown to stimulate GAB2 phosphorylation at Ser159 in a PKA-dependent manner

• Kinase activity assays:

  • Perform in vitro kinase assays with purified PKA or AKT and GAB2 as substrate

  • GAB2 has been shown to be phosphorylated in immune complex phosphorylation reactions in the presence of the catalytic subunit of PKA

• Phospho-specific antibodies with pathway validation:

  • Use anti-phospho-GAB2(Ser159) antibody in cells with constitutively active or dominant-negative forms of PKA or AKT

  • Co-expression with PKA or the T308D/S473D mutant of AKT has been shown to reduce GAB2 tyrosine phosphorylation by 40% and 60%, respectively

• Temporal analysis:

  • Monitor the timing of PKA activation versus AKT activation relative to GAB2 phosphorylation

  • The phosphorylation of GAB2(Ser159) has been shown to precede the phosphorylation of AKT(Ser473) in certain contexts

A comprehensive approach would involve combining these methods to build a complete picture of the kinase(s) responsible in the specific biological context being studied.

Why might researchers observe inconsistent results when detecting phosphorylated GAB2?

Several factors can contribute to inconsistent results when detecting phosphorylated GAB2:

• Rapid dephosphorylation: Phosphorylated proteins can be rapidly dephosphorylated by endogenous phosphatases during sample preparation. Ensure complete and consistent use of phosphatase inhibitors (sodium fluoride, sodium orthovanadate, beta-glycerophosphate).

• Stimulus timing: The phosphorylation of GAB2 at Ser159 is dynamic and timing-dependent. Research shows phosphorylation of GAB2(Ser159) precedes phosphorylation of AKT(Ser473) , suggesting careful time-course experiments are necessary.

• Cell type variability: Different cell types may have varying levels of the kinases (PKA or AKT) responsible for Ser159 phosphorylation. For example, in MCF-7 breast cancer cells, AKT phosphorylates GAB2 on Ser159 , while in other contexts, PKA may be the primary kinase.

• Antibody specificity: Phospho-specific antibodies may have varying degrees of specificity or may be sensitive to blocking conditions. Several commercial antibodies specifically detect GAB2 only when phosphorylated at serine 159 , but performance may vary between manufacturers.

• GAB2 expression levels: Low endogenous expression of GAB2 in some cell types may make detection challenging, requiring immunoprecipitation or enrichment steps.

• Feedback mechanisms: Since Ser159 phosphorylation is part of a feedback inhibition loop, the signaling state of the cells may affect results in ways that are difficult to control consistently.

To address these issues, researchers should standardize protocols rigorously, perform time-course experiments, include appropriate positive controls (e.g., HT29 cells treated with serum ), and consider using multiple detection methods to confirm results.

How should researchers interpret data when observations with Phospho-GAB2 (Ser159) antibodies conflict with other assays?

When faced with conflicting data between phospho-specific antibody results and other assays, consider these interpretative approaches:

• Verify antibody specificity:

  • Confirm antibody specificity using peptide competition assays with phosphorylated vs. non-phosphorylated peptides

  • Test the antibody in systems with S159A GAB2 mutants, which should show no signal

  • The majority of commercial antibodies have been validated to detect endogenous levels of GAB2 only when phosphorylated at serine 159

• Consider post-translational modification crosstalk:

  • Other modifications near Ser159 might affect antibody recognition

  • Tyrosine phosphorylation status might influence the conformation and thus the accessibility of the Ser159 epitope

• Evaluate assay compatibility:

  • Different lysis conditions may preserve phosphorylation to varying degrees

  • Some assays (e.g., immunoprecipitation followed by mass spectrometry) might be more definitive for identifying phosphorylation sites

• Assess functional readouts:

  • Correlate phosphorylation with functional outcomes using GAB2 mutants (S159A)

  • Expression of S159A GAB2 has been shown to enhance HRG-induced Gab2 tyrosine phosphorylation and association with Shc and ErbB2, and markedly increase activation of ERK and PKB pathways

• Contextual interpretation:

  • The phosphorylation state of GAB2 at Ser159 exists in a dynamic equilibrium

  • In FSH-treated cells, the majority of GAB2 (76.0 ± 3.2%, n = 3) is phosphorylated on Ser159 based on antibody depletion experiments

When conflicts arise, cross-validation using multiple techniques (e.g., phospho-specific antibodies, phospho-proteomic mass spectrometry, in vitro kinase assays, and site-directed mutagenesis) provides the most robust interpretation of GAB2 phosphorylation status and its functional significance.

How is GAB2 Ser159 phosphorylation implicated in immune cell signaling and inflammation?

GAB2 plays important roles in immune cell signaling, with Ser159 phosphorylation providing a key regulatory mechanism:

• Mast cell activation: GAB2 is the principal activator of phosphatidylinositol-3 kinase in response to activation of the high affinity IgE receptor, crucial for allergic responses . Phosphorylation status likely regulates this process.

• Neutrophil function: Research has identified GAB2 as a PI3-kinase adaptor in neutrophils that undergoes dual phosphorylation at Ser/Thr and Tyr residues through different types of membrane receptors :

  • GAB2 is Tyr phosphorylated upon stimulation of FcγRII in neutrophil-like cells

  • GAB2 is further Ser/Thr phosphorylated in response to fMLP (a chemotactic peptide)

  • This dual phosphorylation appears important for enhanced superoxide formation

• Signaling integration: GAB2 phosphorylation likely serves as an integration point for signals from multiple immune receptors:

  • G protein-coupled receptors (like fMLP receptors)

  • Tyrosine kinase-linked receptors (like FcγRII)

  • Cytokine receptors

• Inflammatory pathways: Enhanced superoxide formation in response to Fcγ and fMLP stimulation was markedly attenuated when GAB2 Ser/Thr phosphorylation was inhibited , suggesting a role in inflammatory processes.

While the search results don't specifically identify Ser159 as the exact Ser/Thr phosphorylation site in all immune contexts, the proven importance of this site in other systems suggests it may play a similar regulatory role in immune cell signaling and inflammation.

What are the most promising techniques for studying temporal dynamics of GAB2 phosphorylation?

Understanding the temporal dynamics of GAB2 phosphorylation requires specialized techniques beyond standard immunoblotting:

• Live-cell imaging approaches:

  • FRET-based biosensors incorporating GAB2 could reveal real-time phosphorylation dynamics

  • Phospho-specific nanobodies fused to fluorescent proteins might enable visualization of phosphorylation events

• High-temporal resolution biochemical methods:

  • Rapid cell lysis at precisely timed intervals followed by quantitative immunoblotting

  • Phos-tag SDS-PAGE for enhanced resolution of phosphorylated species

  • Research has already shown that phosphorylation of GAB2(Ser159) precedes phosphorylation of AKT(Ser473) , indicating the importance of temporal analysis

• Mass spectrometry-based approaches:

  • Targeted phosphoproteomics with heavy isotope-labeled internal standards

  • SILAC or TMT labeling for quantitative comparison across time points

  • Selective reaction monitoring (SRM) for focused analysis of specific phosphopeptides

• Computational modeling:

  • Integration of experimental data into mathematical models of signaling pathways

  • Sensitivity analysis to identify key regulatory parameters affecting phosphorylation dynamics

• Single-cell analysis techniques:

  • Mass cytometry (CyTOF) with phospho-specific antibodies

  • Single-cell western blotting for heterogeneity analysis

  • Microfluidic approaches for controlled stimulation and analysis

These approaches, especially when used in combination, can provide insights into how GAB2 phosphorylation at Ser159 changes over time in response to various stimuli, how it relates to other phosphorylation events, and how these dynamics influence downstream signaling outcomes.

How might targeting GAB2 phosphorylation be exploited for therapeutic applications?

The emerging understanding of GAB2's role in signaling networks suggests several therapeutic opportunities:

• Cancer treatment approaches:

  • Inhibiting GAB2 function or expression could be valuable in cancer therapy, particularly in AML where GAB2 is essential for FLT3-ITD driven leukemia development

  • Since S159A GAB2 (preventing phosphorylation) has transforming activity in fibroblasts , promoting phosphorylation at this site could potentially suppress oncogenic signaling

• Modulation of immune responses:

  • Given GAB2's role in mast cell activation and neutrophil function , targeting its phosphorylation could potentially modulate allergic and inflammatory responses

  • Inhibitors that prevent the formation of complexes between phosphorylated GAB2 and its effectors might provide targeted immunomodulation

• Combined targeting strategies:

  • Dual targeting of GAB2 and key associated proteins (like PI3K or SHP2) might provide synergistic effects

  • Research shows that leukemic bone marrow from Gab2 deficient mice exhibited increased sensitivity to FLT3 inhibitors , suggesting combination approaches

• Pathway-selective interventions:

  • Since GAB2 integrates and amplifies signals from multiple receptors, selective modulation of GAB2 phosphorylation might allow pathway-specific interventions

  • GAB2 promotes AML aggressiveness by upregulating RTKs like Axl through the Flt3-ITD/Gab2/Stat5 axis

• Development of phosphorylation state-specific modulators:

  • Small molecules that specifically stabilize or disrupt phosphorylated GAB2 interactions

  • Peptidomimetics that mimic phosphorylated GAB2 binding interfaces

While these approaches are largely theoretical at present, the fundamental understanding of GAB2 phosphorylation mechanisms provides a foundation for developing more targeted therapeutic strategies in cancer and inflammatory diseases.

What is the relationship between GAB2 Ser159 phosphorylation and other GAB family proteins?

GAB2 is part of a family of scaffolding proteins that includes GAB1 and GAB3. Understanding the relationships between phosphorylation of these family members is important: